DEFA14A: Enhabit Details Strategic Review Amidst Proxy Fight with AREX Capital

Enhabit files preliminary proxy materials and provides additional details on its strategic review process, which concluded without any actionable proposals despite engaging with 38 potential counterparties.

Summary

• Enhabit has filed preliminary proxy materials for its 2024 annual meeting, where AREX Capital Management is seeking to nominate seven candidates to the nine-member board.
• The filing includes additional information about Enhabit's recently concluded strategic review process, which lasted approximately nine months.
• Goldman Sachs, Enhabit's financial advisor, contacted 38 potential counterparties, including strategic buyers and financial sponsors.
• 26 parties signed non-disclosure agreements, and nine participated in management presentations.
• Four parties provided initial indications of interest, with financial sponsors offering $11 to $12 per share and one strategic acquiror offering $10 per share.
• Another strategic acquiror proposed all-stock consideration without providing a valuation.
• Ultimately, no formal offers were submitted due to headwinds such as regulatory changes in Medicare Advantage rates, a challenging healthcare operating environment, and high interest rates.
• The Board concluded the strategic review on May 8, 2024, after receiving no actionable proposals.
• The company believes that AREX has initiated a proxy contest to take control of the Board in the wake of the extensive strategic review that they demanded.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company highlights the thoroughness of the strategic review, the lack of actionable proposals and the ongoing proxy fight with AREX Capital Management create uncertainty. The negative impact of regulatory changes on the managed care industry also contributes to the lower sentiment score.

Positives

• Enhabit conducted a thorough strategic review process, engaging with a significant number of potential buyers.
• The Board considered various options to enhance stockholder value prior to AREX's involvement.
• The company received an opinion that a strategic review would not cause the spin-off from Encompass to fail as tax-free.

Negatives

• The strategic review process did not result in any actionable proposals.
• Significant headwinds, including regulatory changes and high interest rates, impacted the process.
• AREX Capital Management has initiated a proxy contest to take control of the Board.

Risks

• Regulatory developments related to changes in Medicare Advantage rates could negatively impact the company.
• A difficult healthcare operating environment and persistently high interest rates pose challenges.
• The outcome of the proxy contest with AREX Capital Management is uncertain.
• The company faces risks related to its ability to execute its strategic plans and attract and retain key personnel.

Future Outlook

The Enhabit Board of Directors and management team remain steadfast in their commitment to maximize value for stockholders and will continue to evaluate all opportunities to do so.

Management Comments

• The eight independent directors who have been nominated for reelection to the Enhabit Board at the 2024 Annual Meeting stated that Enhabit's strategic alternatives process was robust and included outreach to a significant number of potentially interested third parties.
• The Board unanimously determined to conclude the strategic review after nine months and having received no actionable proposals.
• The Board remains confident the Company has taken the right steps to improve financial and operational results, enhance growth, and create significant value for all Enhabit stockholders.
• The Board is disappointed that AREX has initiated a proxy contest to take control of the Board in the wake of the extensive strategic review that they demanded.

Industry Context

The announcement highlights the challenges faced by healthcare companies in the current environment, including regulatory changes, high interest rates, and labor shortages. The decline in the median market capitalization of the managed care industry following the CMS rate announcement underscores the sensitivity of the sector to regulatory developments.

Comparison to Industry Standards

• The document mentions that the April 1, 2024 CMS announcement resulted in a broader decline in the median market capitalization of the managed care industry of approximately 6%, based on stock price performance of the Cigna Group, Centene Corporation, CVS Health, Elevance Health, Humana, Molina Healthcare and UnitedHealth Group from April 1 to April 2, 2024.
• This indicates that Enhabit's strategic review process was impacted by industry-wide factors affecting other major players in the managed care space.

Stakeholder Impact

• The outcome of the proxy contest and the company's strategic direction will impact shareholders.
• The company's ability to navigate the challenging healthcare environment will affect employees.
• The company's focus on patient care in the home will continue to impact patients and their families.

Next Steps

• The Company intends to file a definitive proxy statement on Schedule 14A, an accompanying YELLOW proxy card, and other relevant documents with the SEC in connection with such solicitation of proxies from the Company’s stockholders for the Company’s 2024 annual meeting of stockholders.

Key Dates

Keywords

strategic review, proxy contest, AREX Capital Management, Enhabit, merger, acquisition, Medicare Advantage, home health, hospice, Goldman Sachs